CARL

Business Context and Reporting Period

Company: CARLSMED, INC. (CARL)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2026
Business Overview: Carlsmed is a medical technology company developing AI-enabled personalized spine surgery solutions. Its primary offering is the aprevo Technology Platform, which includes surgical planning software and patient-specific interbody implants for lumbar and cervical spine fusion. The company completed its IPO in July 2025 and is classified as an Emerging Growth Company and Smaller Reporting Company.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 57% year-over-year for the six months ended June 30, 2026, driven by higher volumes of lumbar and cervical procedures. Average revenue per procedure remained substantially constant.
• Expense Expansion: Total operating expenses increased 64.6% year-over-year to $47.3 million.
  • General & Administrative (G&A): Increased 103.3% to $13.8 million, primarily due to personnel costs for public company compliance, legal fees, and higher provisions for credit losses.
  • Sales & Marketing: Increased 52.1% to $22.2 million, driven by headcount growth, sales agent commissions, and marketing initiatives.
  • R&D: Increased 53.5% to $11.2 million, reflecting investments in AI surgical planning and product development.
• Profitability: Net loss widened to $19.2 million for the six-month period compared to $12.5 million in the prior year, reflecting the aggressive investment in commercialization and public company infrastructure.
• Interest Income: Increased 141.6% to $1.7 million due to higher cash balances from the July 2025 IPO and increased yields on investments.

Guidance, Outlook, and Risks

• Product Launches: The company commercially launched the aprevo Cervical platform in December 2025. The corra Cervical Plating System completed its first procedure in February 2026, with a full commercial launch expected by December 2026. The aprevo bi-lateral lumbar procedure is planned for a Q4 2026 launch.
• Reimbursement Environment:
  • Lumbar: Effective October 1, 2026, new CMS MS-DRG codes (523, 524, 525) will apply to inpatient lumbar fusions using aprevo, potentially reducing hospital uncertainty and supporting reimbursement.
  • Cervical: Inpatient procedures are eligible for New Technology Add-on Payment (NTAP). However, the requested Transitional Pass-Through (TPT) payment for outpatient cervical procedures was not approved by CMS in November 2025.
• Liquidity: Management believes existing cash ($89.3 million in liquid assets) and available credit ($34.4 million remaining on the term loan) are sufficient to fund operations for at least 12 months.
• Risks: Key risks include dependence on third-party contract manufacturers, the ability to maintain reimbursement rates, regulatory approvals for new indications, and the need for additional capital if growth accelerates faster than anticipated.

Investor Verification Checklist

• Reimbursement Status: Verify the impact of the October 2026 CMS MS-DRG changes on hospital adoption rates and the status of outpatient cervical reimbursement negotiations.
• Debt Covenants: Review the Customers Bank Loan Agreement milestones; the company recently achieved a revenue milestone extending the interest-only period, but future milestones are required to maintain full borrowing capacity.
• Customer Concentration: Confirm that no single customer exceeds 10% of revenue (as stated in the filing) and monitor accounts receivable aging given the increased provision for credit losses.
• Product Pipeline: Track the commercial launch timeline for the corra Cervical Plating System and aprevo bi-lateral lumbar procedures to ensure they meet the stated Q4 2026 targets.
• Cash Burn: Monitor the trajectory of operating cash burn ($20.4 million for six months) against the $89.3 million liquid asset base to assess runway.